TimesSquare Capital Management LLC Purchases 121,898 Shares of Repligen Corporation $RGEN

TimesSquare Capital Management LLC increased its position in Repligen Corporation (NASDAQ:RGEN) by 50.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 362,129 shares of the biotechnology company’s stock after buying an additional 121,898 shares during the quarter. TimesSquare Capital Management LLC owned 0.64% of Repligen worth $48,406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Hantz Financial Services Inc. lifted its holdings in shares of Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 293 shares during the period. CWM LLC raised its position in Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 135 shares during the last quarter. Center for Financial Planning Inc. lifted its holdings in Repligen by 34.2% during the 2nd quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after buying an additional 126 shares during the period. Trust Co. of Vermont bought a new stake in shares of Repligen in the 3rd quarter valued at about $67,000. Finally, Wilmington Savings Fund Society FSB increased its stake in shares of Repligen by 2,750.0% in the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 495 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on RGEN shares. UBS Group lifted their price objective on Repligen from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Canaccord Genuity Group boosted their price target on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. Wall Street Zen upgraded shares of Repligen from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Barclays boosted their target price on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Wells Fargo & Company increased their price target on Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.92.

Repligen Trading Up 2.9%

RGEN opened at $136.44 on Friday. The company has a fifty day moving average price of $159.23 and a two-hundred day moving average price of $145.67. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $175.77. The company has a market cap of $7.68 billion, a P/E ratio of 6,825.41, a price-to-earnings-growth ratio of 2.49 and a beta of 1.13. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26.

Insiders Place Their Bets

In other news, Director Karen A. Dawes sold 275 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director owned 91,821 shares in the company, valued at $14,783,181. This represents a 0.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO James Bylund sold 2,191 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 4,657 shares of company stock worth $706,877 over the last ninety days. Insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.